Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Evogene Ltd. (EVGN) Stock Down -13.34% Today?

Why Is Evogene Ltd. (EVGN) Stock Down -13.34% Today?

Key Takeaways

  • EVGN shares fell 13.34% to $0.3033 in midday trading, down from the prior close of $0.35.
  • The primary catalyst was the third-quarter 2026 report, which showed revenue of $141,000 against a consensus near $365,000 — a miss of roughly 60% and a 55% year-over-year decline.
  • An apparent per-share beat was mechanical: the weighted share count nearly doubled, so a narrower loss per share reflected dilution rather than operating improvement.
  • Secondary drivers include no new collaboration agreements in the quarter, about $2.4 million of quarterly cash use, and continued governance churn at the board level.
  • The decline ran against a firmer tape, with U.S. indices opening higher on Thursday after a major AI listing priced above range, marking the move as company-specific.
  • News Significance Score: 48/100 — a materially negative earnings update paired with a roughly three-times-normal price swing.
  • Traders are watching cash runway, the March 29, 2027 Nasdaq bid-price deadline, and whether the aGVHD and Septoria programs attract a partner.
  • Dive deeper into Price Targets, Earnings, and Forecast pages for full financial detail.
  • Explore Trending AI Robots to see which automated strategies are performing best in the current market.

Opening Summary

Evogene Ltd. (EVGN) is a small, Rehovot, Israel-based computational chemistry company that uses its ChemPass AI platform to design novel small molecules for drug development and crop protection, operating through subsidiaries including AgPlenus and Casterra. In Thursday's session the stock fell 13.34% to $0.3033, down from the previous close of $0.35, a decline of $0.0467 per share. The direction is decisively lower, and the trigger was identifiable: investors reacted to a third-quarter report in which revenue collapsed to near zero on a sequential and annual basis after the Bayer collaboration ended in May 2026, overshadowing a headline loss-per-share beat that was driven by a much larger share count.

Earnings: Revenue Nearly Evaporates

Evogene reported third-quarter revenue of approximately $141,000, against roughly $312,000 a year earlier and a consensus estimate near $365,000 to $400,000. The 54.8% year-over-year decline follows the conclusion of the license and collaboration agreement with Bayer, and nine-month revenue fell to about $822,000 from $3.19 million.

The loss per share of $0.17 beat expectations of about $0.19, but the improvement was arithmetic rather than operational. The weighted average share count rose to roughly 16.9 million from 8.7 million, and shares outstanding reached 18.05 million at quarter-end. Loss from continuing operations widened to about $2.81 million from $2.36 million, while the company swung to a net loss of roughly $2.85 million from prior-year net income that had been inflated by asset sales. For a company valued at only about $6 million, a revenue base that has essentially disappeared is a material negative, and the market priced it accordingly.

Cash Position and the Funding Question

Cash, cash equivalents, and short-term deposits totaled about $9.2 million at September 30, unchanged from the prior quarter only because roughly $2.4 million was raised through share issuance. Quarterly cash use was about $2.4 million, including a $0.5 million directors-and-officers insurance payment, a pace that funds roughly a year of operations. Shareholders' equity attributable to Evogene turned negative at quarter-end, and no full-year cash-usage guidance was reiterated. That combination keeps financing risk — and the prospect of further dilution — at the center of the investment case.

Pipeline Progress Versus Commercial Silence

Management highlighted two internal programs: small-molecule candidates for acute graft-versus-host disease, with IND-enabling work targeted around mid-2027, and AgPlenus fungicide compounds targeting Septoria with up to 75% disease-severity reduction in plant-tissue assays and field work planned for 2027. Both are credible but years from revenue. Critically, no new collaboration agreements were announced in the quarter after four were signed in the first half, removing the catalyst that had supported the stock earlier in the year.

Governance Overhang and Listing Risk

The board appointed Dr. Adi Zuluf-Shani as chairperson effective November 18, following the resignation of the prior chairman disclosed days earlier and the settlement with dissident shareholders approved at the November 10 general meeting. The reshuffle adds uncertainty at the top. Separately, the stock has traded below $1.00 since March 2026, and Nasdaq's extended compliance window runs only to March 29, 2027, with a potential reverse split flagged as a remedy.

Market Context and Trading Activity

The move was company-specific. U.S. indices opened higher Thursday, with the Nasdaq up nearly 2% in early trade after a record AI initial public offering priced above its range, while hawkish Federal Reserve minutes kept pressure on unprofitable micro-caps more broadly. Turnover was light, with roughly 23,000 shares changing hands by midday against a 60-day average near 149,000, a sign the move came from a thin order book rather than heavy institutional distribution. Technically, the stock slipped below its 20-day average near $0.356 and sits about 21% above its 52-week low of $0.2503.

News Significance Score

The score runs from 0 — no meaningful news and a routine move — to 100, meaning transformative news and an extreme, rare price swing. Evogene's update lands at 48 out of 100. The fundamental component is solid but not transformative: a steep revenue miss, a widening operating loss, negative equity, and roughly a year of cash runway are highly material for a $6 million company, yet they confirm an existing narrative rather than break new ground. The move was roughly three times the stock's typical 4.5% daily swing, but a decline of this size has occurred twice in the last 60 sessions, including a 29% jump on November 10. Moderate news plus a moderately unusual move produces a mid-range score.

What Comes Next for EVGN

Attention shifts to the fourth-quarter and full-year report, expected in the first quarter of 2027, and to any update on cash-usage guidance that management declined to reaffirm. The most plausible near-term catalyst is a partnership around the Septoria fungicide program, where early partner interest was cited. Investors will also watch for share issuance or other financing, the March 29, 2027 bid-price deadline, and preclinical progress in the aGVHD program. Risks are concentrated: continued revenue near zero, dependence on capital markets, and the possibility of a reverse split. Nothing is assured in either direction.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the roster shifts as market conditions evolve. For readers who want to see which automated strategies are working right now, reviewing the Trending AI Robots page is a practical next step.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: EVGN

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


EVGN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for EVGN turned positive on November 11, 2026. Looking at past instances where EVGN's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVGN's RSI Indicator exited the oversold zone, 36 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

Following a +8.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVGN advanced for three days, in 142 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

EVGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 35 cases where EVGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVGN as a result. In 82 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EVGN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.302) is normal, around the industry mean (3.592). P/E Ratio (-0.366) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.012) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. EVGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of plant traits for the agriculture and biofuel industries

Industry Biotechnology

Industry
Biotechnology
Address
13 Gad Feinstein Street
Phone
+972 89311900
Employees
52
Web
https://www.evogene.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.